Personal protective equipment induced facial dermatoses in healthcare workers managing Coronavirus disease 2019
Mehak Singh, Manoj Pawar, Atul Bothra, Aditya V. Maheshwari, Vikash Kumar Dubey, Ajeet Ramamani Tiwari, Awatef Kelati
Abstract
characterized by an exaggerated inflammatory response. Another experiment in mouse has documented an inhibitory effect of apremilast on the release of profibrotic cytokine from macrophages, including interleukin-6. 10 During COVID19, pneumonia has been documented a 'cytokines storm', with markedly higher levels of IL-6, and TNF-a, suggesting the use of interleukin-6 receptor blocker tocilizumab in severe cases. Recently, another Italian psoriasis patient contracting COVID-19 under IL-23 inhibitor treatment (guselkumab) has been reported, and completely recovered from the infection. rom our experience, apremilast confirms its safety in very critical patients with severe infections, including COVID-19. Its efficacy in our sub-erythrodermic psoriasis was not completely satisfactory, but other treatments were contraindicated for the recurrent brain oligodendroglioma. Further studies are warrant to explore the intriguing immune modulating activities of this very manageable drug.